Profiel
Peter W.
Letendre served as President, Chief Executive Officer & Director at Pier Pharmaceuticals, Inc. and as a Director at RespireRx Pharmaceuticals, Inc. He was also the Chief Commercial Officer at Replidyne, Inc. from 2005 to 2008.
Letendre received his undergraduate degree in 1980 and his doctorate in 1982 from Massachusetts College of Pharmacy & Health Science.
Eerdere bekende functies van Peter W. Letendre
Bedrijven | Functie | Einde |
---|---|---|
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Corporate Officer/Principal | 15-04-2008 |
RESPIRERX PHARMACEUTICALS INC. | Directeur/Bestuurslid | - |
Pier Pharmaceuticals, Inc.
Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Pier Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company which develops a pharmacologic treatment for obstructive sleep apnea (OSA). It develops Dronabinol a synthetic derivative of the naturally occurring substance in the cannabis plant, namely delta-9-tetrahydrocannabinol, otherwise known as delta-9 THC. The company was founded in 2007 and is headquartered in Louiseville, CO. | Algemeen Directeur | - |
Opleiding van Peter W. Letendre
Massachusetts College of Pharmacy & Health Science | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
RESPIRERX PHARMACEUTICALS INC. | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Health Technology |
Pier Pharmaceuticals, Inc.
Pier Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Pier Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company which develops a pharmacologic treatment for obstructive sleep apnea (OSA). It develops Dronabinol a synthetic derivative of the naturally occurring substance in the cannabis plant, namely delta-9-tetrahydrocannabinol, otherwise known as delta-9 THC. The company was founded in 2007 and is headquartered in Louiseville, CO. | Health Technology |